The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion. Tevogen Bio is an advanced-stage specialty ...
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the ...
Immunotherapy developer Tevogen (TVGN) plans to go public through a merger with SPAC Semper Paratus Acquisition Corp. (NASDAQ:LGST), with the deal estimating the enterprise value of the combined ...
SPAC Semper Paratus Acquisition Corp. (NASDAQ:LGST) shareholders have approved a planned merger with immunotherapy developer Tevogen Bio (TVGN). Semper said in a statement issued Thursday that it was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results